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Abstract 26 
Transforming Growth Factors (TGF)-β regulate tissue fibrosis: TGF-β promotes 27 
fibrosis, whereas Bone Morphogenetic Protein (BMP)-7 is antifibrotic. Aims: To 28 
demonstrate that: (i) Left ventricular (LV) remodeling after pressure overload is 29 
associated to disequilibrium in the signaling mediated by these cytokines; and 30 
(ii) BMP-7 exerts beneficial effects on LV remodeling and reverse remodeling. 31 
Methods and Results: We studied patients with aortic stenosis (AS) and mice 32 
subjected to transverse aortic constriction (TAC) and TAC-release (de-TAC). LV 33 
morphology and function were assessed by echocardiography. LV biopsies 34 
were analyzed by qPCR, immunoblotting and histology. Pressure overload 35 
reduced BMP-7 and pSmad1/5/8 and increased TGF-β and pSmad2/3 in AS-36 
patients and TAC-mice. BMP-7 correlated inversely with collagen, fibronectin 37 
and β-MHC expressions, and with hypertrophy and diastolic dysfunction, and 38 
directly with the systolic function. Multiple linear regression disclosed BMP-7 39 
and TGF-β as hypertrophy predictors, negative and positive, respectively. BMP-40 
7 prevented TGF-β-elicited hypertrophic program in cardiomyocytes, and 41 




with rBMP-7 attenuated the development of structural damage and dysfunction, 1 
and halted ongoing remodeling. The reverse remodeling after pressure overload 2 
release was facilitated by rBMP-7, and hampered by disrupting BMP-7 function 3 
using a neutralizing antibody or genetic deletion. Conclusion: The disequilibrium 4 
between BMP-7 and TGF-β signals plays a relevant role in the LV remodeling 5 
response to hemodynamic stress in TAC-mice and AS-patients. BMP-7 6 
signaling protects the LV against pathological remodeling and might constitute a 7 
therapeutic target to delay or avoid surgery, and to improve the reverse 8 
remodeling after surgery in AS patients. 9 
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AS: Aortic stenosis 16 
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EMT: Endothelial-to-mesenchymal transition  21 
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LVEF: LV ejection fraction  24 
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MAPSE: mitral annular plane systolic excursion  26 
PO: Pressure overload 27 
PWT: LV Posterior wall thicknesses 28 
PWT/LVEDr: Relative PWT to LVED radius 29 
TAC: Transverse aortic constriction  30 





Aortic stenosis (AS) is an age-related valve disorder; it constitutes the 2 
most common adult heart valve disease that requires surgery in the Western 3 
world and it will keep gaining importance due to the progressive increase in life 4 
expectancy in our societies [1]. Sustained pressure overload (PO) stress can 5 
elicit in the LV from AS patients a harmful remodeling, characterized by 6 
concentric hypertrophy and interstitial and perivascular fibrosis [2], which 7 
constitutes a major independent risk factor for heart failure and mortality [3]. 8 
Nowadays, the only effective therapy for symptomatic AS patients is the aortic 9 
valve replacement. After releasing the biomechanical stress, the LV undergoes 10 
a process of reverse remodeling [4,5]. However, when the LV structural damage 11 
is severe the remodeling process becomes irreversible after surgery, which 12 
results in unfavorable short‐ and long‐term outcome of AS patients [4,6,7]. The 13 
lack of preventive therapies of myocardial remodeling in AS patients highlights 14 
need for new effective drugs to delay the progression of LV structural damage 15 
before surgery and to improve and accelerate the reverse remodeling after 16 
releasing the hemodynamic stress. 17 
The transforming growth factor β (TGF-βs) superfamily of cytokines is 18 
composed, among others, by the prototypic TGF-βs and bone morphogenetic 19 
proteins (BMPs). TGF-β and BMP signaling [8] is transmitted by heteromeric 20 
complexes of type I (also termed activin like kinase [ALK]) and type II 21 
membrane receptors, with serine/threonine kinase activity. Upon receptor 22 
activation, the canonical intracellular signals propagate downstream through the 23 
phosphorylation of receptor-activated Smads; p-Smads form complexes with 24 
the common partner, Smad4, which translocate to the nucleus to regulate the 25 
transcription of target genes. The TGF-β subfamily signals through pSmad2/3, 26 
while the BMP family signals through pSmad1/5/8 proteins. These signals can 27 
be controlled by negative-feedback mechanisms via inhibitory Smads  [9,10].  28 
Overproduction of TGF-β contributes to cardiomyocyte hypertrophy and 29 
aberrant synthesis and deposition of extracellular matrix (ECM) which 30 
characterizes the pathological remodeling of the LV under PO in animal models 31 
and in patients suffering from AS or systemic hypertension [11-17]. TGF-βs 32 
promote resident fibroblast proliferation and activation, and stimulate 33 
endothelial-to-mesenchymal transition (EMT), increasing the pool of cardiac 34 
myofibroblasts [11,14]. On the other hand, BMP-7 signaling counteracts TGF-35 
β1-induced accumulation of myofibroblasts and extracellular matrix (ECM) 36 
production in experimental models of progressive interstitial fibrosis affecting 37 
several organs, including the heart [18,19]. In the present study we investigated 38 
the pathophysiological relevance of an imbalance between TGF-β and BMP-7 39 
signaling in the LV remodeling response to PO in patients suffering of severe 40 
AS and in a mouse model of transverse aortic constriction (TAC). The potential 41 
for BMP-7 to prevent, slow, or reverse the LV structural damage induced by PO, 42 
and to improve the LV reverse remodeling after releasing the hemodynamic 43 





Pressure overload studies in mice. 1 
The experiments were performed in 12-16 week old littermate female 2 
wild type (C57BL/6) and heterozygous BMP-7 deficient mice (BMP-7+/-) in a 3 
C57BL/6 genetic background [20]. The study was approved by the University of 4 
Cantabria Institutional Laboratory Animal Care and Use Committee (reference 5 
IP0415) and conducted in accordance with the guidelines from directive 6 
2010/63/EU of the European Parliament. All animals received humane care and 7 
all efforts were made to minimize animal suffering.  8 
Transverse aortic constriction (TAC) and release (de-TAC): Mice 9 
were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and 10 
xylazine (5 mg/kg) and subjected to transverse aortic constriction (TAC) for 4 11 
weeks [16]. In a series of mice, the aortic arch was re-approached and the 12 
constriction was released (de-TAC mice); de-TACmice were followed-up for one 13 
or four weeks. Mice were sacrificed by decapitation under anesthesia (100 14 
mg/kg ketamine and 5 mg/kg xylazine, i.p.). 15 
Treatments: the protocols and number of mice per group are shown in 16 
the supplementary Fig S1. Recombinant murine BMP-7 (rBMP-7, R&D 17 
Systems) was administered at the dose of 10 μg/kg/week using osmotic mini-18 
pumps (Alzet 1002) during: (i) the complete 4 week-TAC period; (ii) the 3rd and 19 
4th weeks following TAC; or (iii) the first week after de-TAC. A monoclonal anti-20 
BMP-7 antibody (clone 164313, R&D Systems) was administered daily (12 21 
μg/day, i.p.) for 7 days starting at the de-TAC surgery.  22 
Echocardiography: Transthoracic echocardiography was performed 23 
with ultrasound equipment [Vevo-770 (VisualSonics, Toronto, ON, Canada) 24 
using a high-resolution transducer centered at 30 MHz]. The operator was 25 
blinded to the study groups. Transcoarctational pressure gradients were 26 
measured using pulsed wave Doppler analysis at the distal arch. LV end-27 
diastolic (LVEDd) and end-systolic (LVESd) internal diameters, interventricular 28 
septum (IVST) and LV posterior wall (PWT) thicknesses were measured 29 
following the recommendations of the American Society of Echocardiography. 30 
The degree of geometric concentricity of the remodeled LV was assessed by 31 
the relative PWT (rPWT) calculated as: rPWT=PWT/(LVEDd/2). Cardiac mass 32 
was estimated using the Devereux’s formula. The mitral annular plane systolic 33 
excursion (MAPSE) measurements were obtained from four-chamber views 34 
using M-mode imaging. The LV ejection fraction (LVEF) and MAPSE were used 35 
as surrogates of short axis and longitudinal systolic functions, respectively. 36 
Parameters of diastolic LV function (E/e') were obtained by pulsed-wave mitral 37 
inflow analysis and tissue Doppler imaging to obtain the ratio of peak early 38 
transmitral flow velocity (E) to peak early myocardial tissue velocity (e′).  39 
Pressure overload studies in patients  40 
 The study followed the Declaration of Helsinki guidelines for biomedical 41 
research involving human subjects. The institutional ethics and clinical research 42 
committee approved the study and all patients gave written informed consent. 43 
The clinical and demographic characteristics of the AS and control groups are 44 
shown in Supplementary Table S1. The study was performed using LV 45 
myocardial intraoperative biopsies obtained from a cohort of 37 patients 46 
diagnosed with isolated severe AS and undergoing aortic valve replacement 47 
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surgery in the University Hospital Marqués de Valdecilla in Santander, Spain. 1 
Patients with aortic or mitral regurgitation greater than mild or with major 2 
coronary stenosis greater than 50%, previous cardiac operations, malignancies 3 
or poor renal or hepatic function were deemed ineligible for the study. The 4 
control group was a cohort of 32 surgical patients with pathologies (atrial septal 5 
defect: n=18, aortic aneurysm: n=7, mitral stenosis: n=4, left atrial myxoma: 6 
n=2, pulmonary valve fibroelastoma: n=1) that did not associate LV pressure or 7 
volume overload, coronary heart disease or cardiomyopathies. Subepicardial 8 
biopsies (4 to 10 mg) were taken from the LV lateral wall with a Tru‐cut needle 9 
during the surgical procedure. 10 
Studies in cultured cells 11 
Rat neonatal cardiomyocytes: Cardiomyocytes were obtained from 12 
Wistar rats sacrificed by decapitation at postnatal day 2–3. The hearts were 13 
removed and kept in Ca2+/Mg2+-free HBBS (Hank´s Balanced Salt Solution) 14 
medium at 4ºC. The tissues were minced using a sterile scalpel blade and 15 
transferred to a T25 flask containing trypsin (1x, Sigma), type IV collagenase 16 
(200 U/ml, Sigma), type I collagenase (0,025 mg/ml, Sigma) and DNase I (0,2 17 
U/ml, Sigma). The flask was settled at 37ºC for 15min and the supernatant was 18 
then collected, mixed with HBBS medium and centrifuged (5min, 1500 rpm). 19 
The cell pellet was re-suspended in DMEM supplemented with 5% FBS and 20 
kept at 37ºC. The harvested cells were plated and incubated for 2 h to allow the 21 
attachment and removal of fibroblasts. The cardiomyocytes were plated 22 
(300,000 cells per well) in M12 multi-well plates pre-coated with 1% gelatin and 23 
cultured in DMEM supplemented with 10%FBS for 48h. The culture medium 24 
was then replaced with OPTI-MEM containing TGF-β1 (5 nmol/ml), BMP-7 (20 25 
nmo/ml) or TGF-β1 (5 nmol/ml) plus BMP-7 (20 nmo/ml) and incubated for 24 h. 26 
The cells were collected and processed for mRNA isolation.  Five independent 27 
experiments were performed. 28 
NIH-3T3 fibroblasts and dual luciferase reporter assays: NIH-3T3 29 
fibroblasts (ATCC, USA) were cultured in DMEM supplemented with 10% FBS, 30 
100 U/ml penicillin-streptomycin, at 37°C in 5% CO2. The cells were seeded in 31 
96 well plates (2x104/well) and cultured for 24 hours in opti-MEM medium. The 32 
cells were co-transfected with pGL3-reporter luciferase vector containing the 33 
promoter of Col1A1 (100 ng/well). The DNA transfection reagent was X-34 
tremeGENE 9 (Roche Diagnostics, Germany). The cells were incubated for 24 35 
h with OPTI-MEM containing TGF-β1 (5 nmol/ml), BMP-7 (20 nmo/ml) or TGF-36 
β1 (5 nmol/ml) plus BMP-7 (20 nmo/ml). Luciferase activity was assessed using 37 
a Luciferase® Reporter Assay (Promega) according to the manufacturer's 38 
specifications. The assays were performed in three wells on two separate 39 
experiments. 40 
mRNA expression 41 
Total RNA was obtained by TRIzol (Invitrogen) extraction. Real‐time q-42 
PCR was conducted using specific TaqMan assays (Applied Biosystems) for 43 
the following genes: BMP-7, TGF-β1, TGF-β2, Smad2, Smad3, Smad7, 44 
collagen I (Col1A1), collagen III (Col3A3), fibronectin 1 (FN1), β-myosin heavy 45 
chain (β-MHC), atrial natriuretic peptide (ANP) and brain natriuretic peptide 46 
(BNP). Gene expression levels were normalized to ribosomal 18S RNA. 47 
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Duplicate transcript levels were determined in a minimum of three independent 1 
experiments. 2 
Histology 3 
Hearts were fixed in paraformaldehyde (3.7% in PBS) for 48 h and 4 
included in paraffin. Four short axis sections (5 μm) at the level of the papillary 5 
muscles (n=4 mice per experimental condition) were stained using Masson’s 6 
trichrome. Digital photographs of the full LV sections were captured using a 7 
camera (Axiocam MRc5, Zeiss) attached to a stereo-microscope (Zeiss 8 
Axiomat). The fractional area of fibrosis was determined (ImageJ software) and 9 
the results were expressed as the blue-stained areas divided by the total LV 10 
myocardial area. The minor diameters of cardiomyocytes from the 11 
subendocardial region of the posterior wall were measured (25 cells per field, 3 12 
fields per mice and 4 mice per group). The operator was blinded to the 13 
experimental group. 14 
Western Blot 15 
Thirty µg of protein lysates were electrophoresed on 10% sodium 16 
dodecyl sulfate-polyacrylamide gel and transferred onto polyvinylidene 17 
difluoride membranes (Bio-Rad, California, USA). The primary antibodies were: 18 
Goat polyclonal to p-Smad2/3 (Santa Cruz Biotechnology, sc-11769), rabbit 19 
poyclonal to p-Smad1/5/8 (cell signaling 9511S); rabbit monoclonal to Smad7 20 
(Abcam, ab90086); mouse monoclonal to BMP7 (R&D, MAB71405); mouse 21 
monoclonal to GAPDH (Santa Cruz, sc-32233); and mouse monclonal to 22 
Tubulin (Sigma-Aldrich, T5168). After incubation with the appropriate secondary 23 
antibodies, proteins were immunodetected with ECL Advance Western Blotting 24 
Detection Kit (GE Healthcare) or with infrared fluorescence (Odyssey imager). 25 
The results were expressed as optical density of the sample dots normalized to 26 
that obtained for GAPDH or tubulin. Samples from 3-6 subjects per group were 27 
tested in two independent experiments. 28 
Statistics 29 
Data were assessed for normality with the Kolmogorov-Smirnov test. 30 
Values were reported as means ± S.E.M. Continuous variables were compared 31 
using two-tailed Student’s t-test or Mann-Whitney U test. The influence of 32 
genotype, drug treatments and PO on gene expression was assessed by a two-33 
way ANOVA, and, on echocardiographic parameters by repeated-measures 34 
two-way ANOVA. Bonferroni post hoc test was used when appropriate. 35 
Correlations between mRNA expression levels were performed using Pearson’s 36 
correlation analysis. Multiple linear regression analysis was used to identify 37 
predictors of LV hypertrophy. Post-hoc assessment of the regression model in 38 
patients was performed with the bootstrapping method with 2,000 iterations. 39 
Significance levels: *p<0.05, **p<0.01, ***p<0.001. Statistical packages: 40 
GraphPad Prism 5.03 and PASW Statistics 18 (SPSS Inc., Chicago, IL).  41 
 42 
Results 43 
LV remodeling involves unbalance between TGF-β1- and BMP-7-mediated 44 
signaling in a mouse model of pressure overload.  45 
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TAC caused a stable trans-coarctational pressure gradient of ≈50 mmHg 1 
during the 4 week follow-up period (Fig 1A). PO resulted in the development of 2 
a rapid progressive LV hypertrophy with concentric geometry (increased 3 
LVPWT/LVEDr), which was accompanied by LV systolic functional deterioration 4 
both in the radial (LVEF) and longitudinal axes (MAPSE), and diastolic 5 
dysfunction reflected by the rise in the LV filling pressure (E/e′). Four weeks 6 
after TAC, mice were subjected to de-TAC surgery and the morpho-functional 7 
echocardiographic evolution was followed for 4 further weeks (Fig 1A). The 8 
release of overload stress activated the reverse remodeling process; as a 9 
result, LV mass decreased and LVEF, MAPSE and E/e′ improved significantly 10 
within the first week after de-TAC. Then, recovery continued at a more gradual 11 
rhythm and at 4 weeks, even though LVEF and E/e′ had already normalized 12 
their values, LV mass and MAPSE had not yet returned to baseline figures (Fig 13 
1A). 14 
LV expression of BMP-7 mRNA (Fig 1B) was significantly reduced in 15 
mice subjected to TAC, whereas the transcript levels of TGF-β1 and TGF-β2 16 
underwent up-regulation; consequently, the ratios TGF-βs/BMP-7 increased 17 
significantly. The mRNA levels of the inhibitory Smad7 were significantly 18 
reduced (Fig 1B). Protein levels of p-Smad2/3 increased while those of p-19 
Smad1/5 and Smad7 diminished (Fig 1C).  20 
Four weeks after releasing the overload stress, the expression levels of 21 
BMP-7, the ratios TGF-β1/2 to BMP-7, and the expressions of p-Smad2/3, p-22 
Smad1/5/8 and Smad7 recovered the control values (Figs 1B and C).   23 
Lineal regression analysis, performed in the cohorts of TAC and de-TAC 24 
mice, show that BMP-7 in the LV correlated significantly and inversely with the 25 
mRNA levels of TGF-β1 and TGF-β2, and directly with those of the inhibitory 26 
Smad7 (Fig 2A). Additionally, the transcript levels of BMP-7 correlated 27 
significantly and inversely with the expression of genes encoding extracellular 28 
matrix elements (Col1A1, Col3A3 and FN-1) (Fig 2B), consistent with the 29 
antifibrogenic properties of this cytokine.  30 
Both, the sarcomeric hypertrophic marker β-MHC (Fig 2B) and LV mass 31 
correlated negatively with BMP-7 (Fig 2C), suggesting an anti-hypertrophy role 32 
for BMP-7. Thus, multiple regression analysis (Fig 2D) indicated that the 33 
myocardial expression of BMP-7 constituted an independent negative predictor 34 
of LV posterior wall thickening after TAC, whereas TGF-β2 was a positive 35 
predictor. The regression equation was the following: PWT (mm) = 0.73 - 36 
1.45*[BMP-7] + 0.2*[TGF-β2]. The adjusted R2 (0.53; p<0.001) indicates that 37 
53% of the variance in PWT after TAC can be estimated from this model. 38 
Regarding the echocardiographic functional parameters, BMP-7 39 
transcript levels correlated inversely with the mean trans-coarctation gradient in 40 
TAC mice (R = 0.52**), indicating a relationship between the severity of the 41 
constriction and BMP-7 down-regulation. Moreover, the systolic function was 42 
positively related to myocardial BMP-7, both in the short-axis (LVEF) and in the 43 
long-axis (MAPSE); while the degree of diastolic dysfunction, as reflected by the 44 
increase in E/e′, was inversely related to BMP-7 mRNA levels  (Fig 2C).  45 
BMP-7 inhibits TGF-β-induced hypertrophic program in primary cultures 46 
of cardiomyocytes 47 
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In cultured neonatal rat ventricular cardiomyocytes, the addition of 1 
recombinant BMP-7 (20 ng/ml) to the culture medium reduced significantly the 2 
overexpression of the hypertrophy markers, ANP, BNP and β-MHC, induced by 3 
TGF-β (3 ng/ml) (Fig 3A). 4 
BMP-7 prevents TGF-β-induced transcriptional activation of the Col1A1 5 
promoter in NIH-3T3 fibroblasts. 6 
The stimulation with TGF-β1 (3 ng/ml) of NIH-3T3 fibroblasts, transfected 7 
with a full-length promoter of COL1A1-Luc construct, resulted in significant 8 
increase of the luciferase activity. BMP-7 (20 ng/ml) significantly repressed 9 
transcriptional activation of COL1A1Pro-luc by TGF-β1 (3 ng/ml) (Fig 3B). 10 
Sustained treatment with recombinant BMP-7 protects the LV from 11 
remodeling under biomechanical stress  12 
The usefulness of rmBMP-7 as pre-emptive treatment against LV 13 
remodeling and to stop the ongoing pathological remodeling response was 14 
assessed under the following experimental conditions (Fig S1): (i) mice treated 15 
with a 4-week subcutaneous infusion of rmBMP-7 starting at the moment of 16 
TAC surgery (BMP-71-4wk group); (ii) mice treated with a 2-week subcutaneous 17 
infusion rmBMP-7 starting on day 15 after TAC surgery when LV hypertrophy 18 
and functional deterioration were already taking place (BMP-73-4wk group); and 19 
(iii) TAC mice treated with a 4-week subcutaneous infusion of saline as control 20 
group. 21 
TAC caused similar trans-coarctation pressure gradients (Fig 4A) in 22 
saline and rmBMP-7 treated mice at any time of the follow-up, indicating similar 23 
degrees of constriction in all groups. The administration of rmBMP-7 during the 24 
4 week TAC follow-up period diminished PO-induced PW and IVS thickening as 25 
well as chamber dilation; as a result, BMP-71-4wk mice developed a significantly 26 
lower degree of LV hypertrophy as compared with saline treated mice. BMP-7 27 
completely prevented TAC-induced systolic dysfunction in the short-axis 28 
(LVEF), and the LV systolic function in the long-axis (MAPSE) was significantly 29 
less impaired in BMP-71-4wk than in the saline group. The rise in E/e’ induced by 30 
TAC was completely prevented by BMP-71-4wk, which indicates a protection 31 
against the development of diastolic dysfunction (Fig 4A). 32 
The treatment with rmBMP-7 during the complete TAC period prevented 33 
myocardial overexpression of the remodeling-related genes analyzed (TGF-β1, 34 
TGF-β2, Col1A1, Col3A3, FN1 and β-MHC) (Figs 5A-F), and attenuated the 35 
structural remodeling, as indicated milder histological fibrosis and shorter 36 
cardiomyocyte diameters displayed by BMP-71-4wk compared with saline treated 37 
mice (Figs 5G-I) .  38 
The administration of rmBMP-7 during the 3rd and 4th weeks of TAC 39 
halted the progression of wall thickening, LV hypertrophy, chamber dilation and 40 
systolic and diastolic dysfunctions (Fig 4A). The expressions of the remodeling-41 
related genes were lower in BMP-73-4wk than in TAC mice treated with saline 42 
(Figs 5A-F). At the structural level, the average cardiomyocyte diameter (Fig 5I) 43 
was significantly smaller, and the LV area occupied by histological fibrosis (Figs 44 
5G and H) displayed a decremental trend, but without statistical significance 45 
due to the interindividual variability.  46 
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Overall, our results indicate that down-regulation of BMP-7 during the 1 
hemodynamic stress condition was a relevant maladaptive feature of 2 
myocardial remodeling and that sustained administration of recombinant BMP-7 3 
prevented PO-induced myocardial hypertrophy, structural damage and systolic 4 
and diastolic dysfunctions. Moreover, when treatment begins once the 5 
pathological myocardial remodeling has been established, BMP-7 can stop the 6 
progression of the ongoing structural damage and its deleterious functional 7 
consequences. 8 
BMP-7 deficiency potentiates LV hypertrophy in BMP-7+/- mice under 9 
biomechanical stress  10 
BMP-7+/- mice exhibited at baseline significantly larger thicknesses of LV 11 
walls and LV mass than their WT littermates. No differences between 12 
genotypes were evidenced in chamber dimensions, systolic and diastolic 13 
functions. Following TAC, the two genotypes developed similar 14 
transcoarctational gradients (wild type: 46.1±3.1 mmHg; BMP-7+/-: 45.6±2.5 15 
mmHg). However, BMP-7+/- mice developed greater levels of LV hypertrophy 16 
and a more concentric LV geometry than wild type mice. The systolic (LVEF 17 
and MAPSE) and diastolic (E/e′) functions displayed a similar deterioration in 18 
both genotypes at any time after TAC (Fig 4B). At the structural level (Fig 6B), 19 
the average diameter of cardiomyocytes was larger in BMP-7+/- than in their wild 20 
type littermates both at baseline and after TAC. The degree of myocardial 21 
fibrosis developed was higher in BMP-7+/- than in C57BL/6 mice.  22 
LV reverse remodeling in mice is hampered by BMP-7 signaling loss-of-23 
function and improved by recombinant BMP-7 24 
Four weeks after TAC a series of mice were subjected to de-TAC 25 
surgery. Given that the bulk of the remodeling regression had occurred within 26 
the first week after de-TAC (Fig 1A), the follow-up of this part of the study was 27 
limited to one week after de-TAC surgery. We assessed the influence of BMP-7 28 
signaling loss-of-function on the capability of the heart to reverse the LV 29 
remodeling after PO release by de-TAC surgery (Fig 6). The subjects of study 30 
(see Fig S1) were the following: (i) TAC-BMP-7+/- mice treated with a 31 
subcutaneous saline infusion during 7 days after de-TAC; (ii) TAC-WT mice 32 
treated with daily injections of a specific monoclonal neutralizing antibody 33 
against BMP-7 (BMP-7-Ab, 500 µg/kg/day, 7 days) starting at the moment of 34 
de-TAC surgery; and (iii) TAC-WT mice treated with a subcutaneous saline 35 
infusion during 7 days after de-TAC. 36 
The transcoarctational gradient fell significantly after de-TAC surgery with 37 
no differences between groups (de-TAC+saline: 16.9±2.3; de-TAC BMP-7+/-38 
+saline: 12.5±1.2; de-TAC+BMP-7-Ab: 17.6±1.1). Both, heterozygous deletion 39 
of BMP-7 and BMP-7 neutralization with a BMP-7-Ab during the 7 day de-TAC 40 
period hampered the LV morpho-functional recovery after releasing the 41 
hemodynamic stress. Regression of LV hypertrophy and the recovery of systolic 42 
(LVEF and MAPSE) and diastolic (E/e′) functions were significantly worse in 43 
both groups of loss-of-BMP-7 function in comparison with C57BL/6 mice treated 44 
with saline (Fig 6A). At the structural level (Fig 6B), the remaining fibrosis and 45 
the average cardiomyocyte diameter after 1-wk de-TAC were significantly 46 
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higher in BMP-7+/- mice and in mice treated with BMP-7-Ab than in wild type 1 
littermates treated with saline. 2 
The effect of BMP-7 gain-of-function on reverse remodeling was 3 
assessed in a series of wild type mice treated with rmBMP-7 during the 7-day 4 
de-TAC period (Fig 6A). The loss of LV mass during the first de-TAC week was 5 
significantly higher in rmBMP-7-treated than in saline-treated mice. Chamber 6 
dilation (LVEDd and LVESd; not shown) decreased and systolic function (LVEF 7 
and MAPSE) improved to a significantly greater extents with rmBMP-7 than with 8 
saline treatment during the first week after de-TAC. At the structural level (Fig 9 
6B), both saline- and rmBMP-7-treated mice reduced the cardiomyocyte 10 
diameter and LV fibrosis area to similar extents.  11 
Translation of the results obtained in the experimental model to the 12 
clinical aortic stenosis  13 
The LV myocardium from AS patients exhibited significantly lower BMP-7 14 
and higher TGF-β1 preoperative expression levels compared with surgical 15 
controls (Fig 7A). BMP-7 mRNA levels in the AS patients’ heart correlated 16 
significantly and inversely with the gene expression of TGF-β1 and directly with 17 
SMAD7 (Fig 7B). As observed in TAC mice, the myocardial gene expression of 18 
BMP-7 correlated inversely with the expressions of Col1A1 and Col3A3 (Fig 19 
7B), and there was a significant and positive association between BMP-7 20 
expression and the systolic function in the short axis (LVEF). Consistent with an 21 
antihypertrophic effect induced by BMP-7, there was an inverse and significant 22 
relationship between the cytokine and the LV mass (Fig 7B). Stepwise multiple 23 
linear regression analysis (Fig 7C) evidenced that preoperative BMP-7 was a 24 
significant negative predictor of the LV mass, whereas TGF-β1 appeared as a 25 
significant positive predictor. The regression equation was the following: LV 26 
mass (g) = 257.5 - 111.6*[BMP-7] + 21.3*[TGF-β1]. The adjusted R2 (0.45; 27 
p<0.001) indicated that 45% of the variance in LV mass can be estimated from 28 
this model in AS patients.  29 
Discussion 30 
Our findings in patients with severe AS and in a mouse model of 31 
reversible pressure overload raise two important notions: (i) an imbalance 32 
between BMP-7 and TGF-β signals could play a major etiopathogenic role in 33 
the maladaptive LV remodeling under pressure overload; and (ii) strategies to 34 
enhance the activity of BMP-7 signaling may have putative therapeutic value to 35 
attenuate ongoing myocardial hypertrophy and to favor the reverse remodeling 36 
after releasing the LV from the hemodynamic load.  37 
TGF-β and BMP-7 belong to the same superfamily, however, each of 38 
these cytokines exhibit a unique signaling pathway through specific Smad 39 
proteins that determine some effects that are opposite in each pathway 40 
[8,18,19]. During the process of pathological remodeling induced by 41 
hemodynamic stress, TGF-β is a primary and potent mediator of myocardial 42 
fibrosis and hypertrophy both in mice and humans [11-17]. On the other hand, 43 
BMP-7 acts as an anti-fibrotic cytokine in experimental models of pathological 44 
organ fibrosis [18,19,21-26]. Our current results evidenced that pressure 45 
overload resulted in biased cellular signaling towards pro-fibrogenic cytokines of 46 
the TGF-β family in detriment of BMP-7-mediated signals, both in TAC mice and 47 
11 
 
in AS patients. We observed LV up-regulation of TGF-βs and down-regulation 1 
of BMP-7 expressions and increased TGF-βs/BMP-7 ratio. Accordingly, the 2 
levels of BMP-7 canonical down-stream effectors (pSmads1/5/8) were reduced 3 
while those of TGF-β (pSmad2/3) appeared increased. In the group of pressure-4 
overloaded mice, the balance between TGF-βs and BMP-7 signaling recovered 5 
normal values after releasing the hemodynamic stress by de-TAC. Furthermore, 6 
myocardial mRNA levels of BMP-7 and those of TGF-βs correlated inversely 7 
both in the cohort of operated mice and in AS patients. These results support 8 
the existence of a reciprocal inhibition between BMP-7 and TGF-β in the heart, 9 
and suggest its clinical relevance in human cardiac remodeling diseases.  10 
TGF-β signaling is modulated by inhibitory Smads. Smad7 binds TGF-β 11 
type I receptor and inhibits Smad2/3 phosphorylation [8,9]. Down-regulation of 12 
Smad7 has been reported to potentiate TGF-β-mediated post-infarct fibrosis in 13 
rats [27]; conversely, recombinant Smad7 protects against angiotensin II-14 
induced hypertensive cardiac remodeling in mice [28]. Our present results show 15 
that Smad7 was down-regulated in the LV from TAC mice and AS patients, 16 
which suggest its contribution to the strengthened TGF-β biased fibrotic 17 
signaling. In cultured cells, BMP-7 induces Smad7 transcription by interacting 18 
with BMP responsive elements in the promoter [29]; therefore, BMP-7 down-19 
regulation in the pressure overload condition could release TGF-β signaling 20 
from the Smad7 antagonistic activity.  21 
   BMP-7 prevents and even reverses, in vitro, TGF-β-induced EMT, 22 
fibroblast accumulation and transdifferentiation into myofibroblasts, blocks the 23 
production of ECM proteins by these cells, and stimulates MMP-2-dependent 24 
breakdown of the fibrotic matrix [18,19,30-32]. Our findings in vivo show that the 25 
transcript levels of BMP-7 kept an inverse relationship with the expression of 26 
Col1A1, Col3A3 and FN1 in the LV from TAC mice. Moreover, the luciferase-27 
reporter assays indicate that BMP-7 inhibits Col1A1 promoter transcription 28 
activity induced by TGF-β in cultured NIH-3T3 fibroblasts. Interstitial fibrosis is a 29 
major cause of LV wall stiffening, diastolic and systolic dysfunction and 30 
progression to heart failure [2,33]. Accordingly, BMP-7 expression in TAC-mice 31 
was related directly to parameters of systolic function (LVEF and MAPSE), and 32 
inversely to the degree of diastolic dysfunction, reflected by the LV filling 33 
pressure (E/e′).  34 
LV hypertrophy, although long considered beneficial to preserve fiber 35 
shortening in the afterload excess condition [3], is now recognized as an 36 
independent predictor of cardiovascular events as well as of global and 37 
cardiovascular mortality [34-36]. Persistence of LV hypertrophy after aortic 38 
valve replacement in AS patients stands as a limiting factor for short and long-39 
term outcome [4-7], whereas LV mass normalization constitutes an independent 40 
positive predictor of long-term survival in multivariate analysis [37]. BMP-7 has 41 
been reported to be involved in cardiac myogenesis in the chick embryo [38], 42 
and BMP type I and type II receptors and signaling pathways are functional in 43 
cardiac myocytes from humans, mice and rats [39]. However, to our knowledge, 44 
there are no studies addressing a possible role for BMP-7 in the regulation of 45 
cardiomyocyte function and pathophysiology. Our data strongly suggest that 46 
BMP-7 exerts an antihypertrophic effect. Such statement is based upon the 47 
following findings: (i) In TAC-mice, there was an inverse relationship between 48 
12 
 
BMP-7 gene expression and LV mass, which is concordant with the negative 1 
correlation between the expressions of BMP-7 and the hypertrophy marker, β-2 
MHC. (ii) The treatment with recombinant BMP-7 after TAC attenuated 3 
significantly the degree of LV hypertrophy developed. (iii) BMP-7+/- mice, 4 
compared to wild type, exhibited a higher LV wall thickness and LV mass at 5 
baseline and, under PO, and developed a greater degree of LV hypertrophy 6 
with more concentric geometry. (iv) Regression of LV hypertrophy after de-TAC 7 
was improved by recombinant BMP-7 while it was hampered by BMP-7 loss-of 8 
function. (v) Multiple regression analysis in TAC mice showed that myocardial 9 
transcript levels of BMP-7 and TGF-β2 constituted significant independent 10 
predictors, negative and positive respectively, which can explain as much as 11 
53% of the variance in PW thickness after 4 weeks of TAC. (vi) rmBMP-7 12 
inhibited the capability of TGF-β to activate in vitro the cardiomyocyte 13 
“hypertrophic gene program,” of which ANP, BNP and β-MHC are prototypical 14 
members [40].   15 
Most of the results obtained in the experimental model can be translated 16 
into a prevalent clinical condition of PO such as aortic valve stenosis. Thus, the 17 
LV from severe AS patients exhibited a lower BMP-7 expression and a higher 18 
TGF-β/BMP-7 ratio compared with surgical controls and both transcripts 19 
correlated inversely. As observed in TAC-mice, BMP-7 mRNA expression levels 20 
in the LV from AS patients correlated inversely with those of Col1A1 and 21 
collagen III as well as with the systolic function in the short axis (LVEF). Also, 22 
multiple regression analysis in AS patients showed that myocardial transcript 23 
levels of BMP-7 and TGF-β1 constituted significant independent predictors, 24 
negative and positive respectively, of the LV mass variance (46%).  25 
Overall, our findings strongly suggest that, during the myocardial 26 
remodeling process in mice and patients, lower myocardial expression levels of 27 
BMP-7 associate higher TGF-β signaling, more severe structural damage and 28 
stronger functional echocardiographic abnormalities. Interestingly, a previous 29 
report on patients with type 2 diabetes mellitus shows that the circulating levels 30 
of BMP-7 and TGF-β1 are better predictors (negative and positive, respectively) 31 
of the future decline in kidney function than conventional markers [41].  32 
In line with a protective effect against pathological remodeling, the 33 
treatment of TAC-mice with exogenous rmBMP-7 during the complete follow-up 34 
period after TAC prevented the development of myocardial fibrosis and, as a 35 
result, the systolic (LVEF and MAPSE) and diastolic (E/e′) functional 36 
deteriorations were significantly attenuated when compared with saline treated 37 
TAC-mice. From a clinical point of view, a major finding of our study is that 38 
BMP-7 not only prevented LV remodeling, but also halted its progression when 39 
the treatment started on day 14th after TAC, when LV hypertrophy and 40 
functional deterioration were already taking place. In these animals, the 41 
progression of the LV hypertrophy and chamber dilation ceased, the 42 
overexpression of ECM-related genes and histological fibrosis tapered and 43 
there was a tendency to improve the systolic function, in both the radial (FEVI) 44 
and longitudinal (MAPSE) axes, as well as the diastolic function. Furthermore, 45 
BMP-7 signaling also seems to play a relevant positive role in the reverse 46 
remodeling process after releasing PO, as evidenced our pharmacological and 47 
genetic approaches. Both, the treatment of mice with a BMP-7 neutralizing 48 
13 
 
antibody, and BMP-7 haploinsufficiency hampered significantly the ability of the 1 
LV to recover the normal myocardial structure and function after de-TAC. On 2 
the contrary, exogenously administered rmBMP-7 improved some features of 3 
the reverse remodeling; particularly hypertrophy, chamber dilation and radial 4 
systolic function were significantly improved during the de-TAC recovery period 5 
by this treatment. 6 
The putative benefit of the activation of BMP-7 signaling to resolve 7 
established organ damage has been investigated in rodent models of renal, 8 
hepatic and pulmonary progressive fibrosis [21-26]. Of note, small peptide 9 
agonists of the ALK3 type of BMP-7 receptors have been generated to inhibit 10 
kidney inflammation, tissue damage and fibrosis [25], and one such peptide, 11 
THR–184, is currently being evaluated in clinical studies of renal injury (NIH, 12 
ClinicalTrials.gov Identifier: NCT01830920). 13 
In summary, our findings support that the imbalance between BMP-7 and 14 
TGF-β opposing signals may play an important role in the remodeling response 15 
of the heart to the hemodynamic stress. The results strongly suggest that BMP-16 
7 signaling might constitute a new therapeutic target for the palliative treatment 17 
of AS patients with severe, although asymptomatic, LV remodeling in order to 18 
delay or even avoid surgery. Additionally, the improvement by pharmacologic 19 
means of LV reverse remodeling after valve replacement could have positive 20 
consequences in the short- and long-term survival and clinical status of these 21 
patients. 22 
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Figure 1. A: Echocardiographic morphological and functional changes induced 2 
by pressure overload in mice subjected to 4 week transverse aortic constriction 3 
(TAC, n=17), and their recovery 4 week after releasing the aortic constriction 4 
(de-TAC, n=8). Data are expressed as mean ± SEM Repeated-measures 5 
ANOVA followed by Bonferroni’s test. B: Myocardial mRNA levels of BMP-7, 6 
TGF-β1 and TGF-β2 and the ratios between TGFβs and BMP7 in sham, TAC 7 
and de-TAC mice. ANOVA followed by Bonferroni’s test (sham, n=7; TAC, n=8; 8 
de-TAC, n=7). C: Myocardial levels of Smads in sham (n=4), TAC (n=5) and de-9 
TAC (n=4) mice.  pSmad1/5/8 and pSmad2/3 were determined by western blot. 10 
The optical density was normalized to tubulin or GAPDH and expressed as 11 
percentage of change vs sham mice. Smad7 was determined by qPCR (sham, 12 
n=6; TAC, n=6; de-TAC, n=7) and western blot (n=4 mice per group). 13 
Representative western blots belong to the same gel. ANOVA followed by 14 
Bonferroni’s test (see supplementary statistical analysis). RE: Relative mRNA 15 
expression normalized to 18S.  16 
 17 
Figure 2.  Linear regression and Pearson′s correlation analyses showing the 18 
relationship of BMP-7 mRNA expression with elements of TGF-β signaling (A), 19 
remodeling-related genes (B), and morpho-functional echocardiographic 20 
parameters (C) in the LV myocardium from TAC (n=7-17 mice) and de-TAC-21 
mice (n=7). R: Pearson′s correlation coefficient. D: Multiple linear regression 22 
model for predicting the posterior wall thickness after 4 weeks of TAC (n=17). 23 
Adjusted R2=0.53 (p<0.001). RE: Relative mRNA expression normalized to 24 
18S. 25 
 26 
Figure 3. The effects of BMP-7 on TGF-β-induced hypertrophic program in 27 
cultured cardiomyocytes (A to C). Relative mRNA expression (RE vs18S) of the 28 
hypertrophy markers ANP, BNP and β-MHC were determined by q-PCR in five 29 
independent experiments. D: Effect of recombinant BMP-7 on TGF-β1-induced 30 
luciferase activity in NIH-3T3 cells transfected with the promoter region of 31 
Col1A1 in a luciferase reporter vector.  Cells were treated with TGF-β1 (5 32 
nmol/ml), BMP-7 (20 nmo/ml) or TGF-β1 (5 nmol/ml) plus BMP-7 (20 nmo/ml). 33 
The luciferase assay was performed in three wells on two separate 34 
experiments. ANOVA followed by Bonferroni’s test (see supplementary 35 
statistical analysis). 36 
 37 
Figure 4. A: Echocardiographic morpho-functional changes induced by 38 
pressure overload in TAC-mice. PWT: LV Posterior wall thicknesses; LVESd: 39 
LV end systolic diameter; LVEDd: LV end diastolic diameter; PWT/LVEDr: 40 
Relative PWT to LVED radius; LVEF: LV ejection fraction; MAPSE: mitral 41 
annular plane systolic excursion; E/e′: ratio of peak early transmitral flow 42 
velocity (E) to peak early myocardial tissue velocity (e′). Data are expressed as 43 
mean ± SEM. A: Mice were treated with saline (n=8, open circles), rBMP7 44 
during the 4 week TAC period (n=5, black circles) or rBMP7 during the 3rd and 45 
4th weeks after TAC (n=8, black squares). Two way repeated-measures ANOVA 46 
19 
 
followed by Bonferroni’s test (*TAC-saline vs. TAC-BMP-71-4wk; #TAC-saline vs. 1 
TAC-BMP-73-4wk). B: Wild type (n=8, open circles) and BMP-7+/- mice (n=15, 2 
black circles) follow-up. (See supplementary statistical analysis). 3 
 4 
Figure 5. Myocardial mRNA expression levels of TGF-βs (A: TGF-β1 and B: 5 
TGF-β2), fibrosis markers (C: Col I, D: Col III and E: FN-1) and hypertrophy 6 
marker (F: β-MHC) in sham (n=6-12), TAC-saline (n=8-11), TAC-BMP-71-4wk 7 
(n=5) and TAC-BMP-73-4wk (n=6) mice. G: Representative images of Masson 8 
trichrome–stained LV sections showing myocardial fibrosis in blue. The 9 
percentage of the LV area occupied by fibrosis (H) and the average diameter of 10 
cardiomyocytes (I) were determined in 4 LV sections from 3-6 mice per group. 11 
ANOVA followed by Bonferroni’s test (see supplementary statistical analysis). 12 
 13 
Figure 6. Effects of BMP7 loss- and gain-of function on the reverse remodeling 14 
during the first week after de-TAC. In a series of mice, four weeks after TAC the 15 
aortic constriction was removed (de-TAC) and mice were followed-up for one 16 
week after de-TAC. C57BL6 mice were treated with saline (n=8), a BMP7 17 
neutralizing antibody (n=6, BMP7-Ab) or recombinant BMP7 (n=5). BMP7+/- 18 
mice were treated with saline after de-TAC (n=7). A: LV hypertrophy regression 19 
after de-TAC. Recovery of systolic function in the short axis (LVEF). C: 20 
Recovery of systolic function in the long axis (MAPSE). Reduction of LV loading 21 
pressure (E/e’). Data are expressed as mean ± SEM of the percentage of 22 
change vs 4 wk-TAC. B: The percentage of fibrosis and the cardiomyocyte 23 
diameter were measured in LV sections from 3-6 mice per group stained with 24 
Masson trichrome. Data are means ± SEM. ANOVA followed by Bonferroni’s 25 
test (see supplementary statistical analysis). 26 
 27 
Figure 7. A: Myocardial expression of BMP-7, TGF-β1 and Smad7 in the LV 28 
from AS (n=38) and surgical control patients (n=32) determined by qPCR and 29 
western blot (n=3-4 patients per group). In each representative western blot, the 30 
dots belong to the same gel. Mann Witney U test. B: Linear regression and 31 
Pearson′s correlation analyses showing the relationship of BMP-7 mRNA levels 32 
with TGF-β1, Smad7, collagens I and III, LV mass index (LVMI) and LV ejection 33 
fraction (LVEF). R: Pearson′s correlation coefficient. C: Significant preoperative 34 
predictors of LV mass in AS patients undergoing aortic valve replacement 35 
(n=38). Adjusted R2=0.53 (p<0.001). RE: Relative expression normalized to the 36 
ribosomal subunit 18S. 37 
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ACE = Angiotensin converting enzyme; AT-II = Angiotensin II 
 
Variable  Aortic Surgical 
   Stenosis Controls 
n  38 32  
Age (yrs ± SD)  71.2±10.1 53.6±15.5  
Male/Female (n)  21/17 10/23  
Systolic blood pressure, mm Hg  129.4±29.9 120.1±18.0  
Diastolic blood pressure, mm Hg  67.5±10.9 69.8±10.4  
Body Mass Index, kg/m2  27.9±6.1 28.2±4.9  
Systemic hypertension  52% 44% 
Diabetes Mellitus  22% 6%  
ACE inhibitors  24% 16% 
AT-II receptor antagonists  10% 13% 
Diuretics  41% 28% 
Calcium antagonists  12% 3 9%  
-Blockers  28% 31% 
Statins  30% 6%  
Supplementary Material - Other
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2 
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Figure 1. 
A: Repeated-measures ANOVA followed by Bonferroni’s test.  
Mean trans-coarctation pressure gradient; CAT (Follow-up time: F(4,84)=119.3, 
p<0.001); de-CAT (Follow-up time: F(3.30)=176.4, p<0.001).  
Posterior wall thickness: CAT (Follow-up time: F(4,84)=158.9, p<0.001); de-
CAT (Follow-up time: F(3,30)=54.3, p<0.001).  
LV mass: CAT (Follow-up time: F(4,84)=114.8, p<0.001); de-CAT (Follow-up 
time: F(3,30)=45.1, p<0.001).  
LV end diastolic diameter: TAC (Follow-up time: F(4,84)=3.85, p<0.01).  
Relative PWT to LVED radius: TAC (Follow-up time: F(4,84)=12.2, p<0.001); 
de-TAC (Follow-up time: F(3,30)=11.0, p<0.001).  
LV ejection fraction: TAC (Follow-up time: F(4,84)=37.4, p<0.001); de-TAC 
(Follow-up time: F(3,30)=36.1, p<0.001).  
Mitral annular plane systolic excursion: TAC (Follow-up time: F(4,84)=31.1, 
p<0.001); de-TAC (Follow-up time: F(3,30)=18.8, p<0.001)].  
Ratio of peak early transmitral flow velocity (E) to peak early myocardial tissue 
velocity (e′): [TAC (Follow-up time: F(4,40)=24.9, p<0.001); de-TAC (Follow-up 
time: F(3,30)=28.5, p<0.001)].  
B: ANOVA followed by Bonferroni’s test.  
BMP7: F(2,20)=6.56, p<0.01; TGF-β1: F(2,21)=7.68, p<0.01; TGF-β2: 
F(2,21)=47.5, p<0.001; TGF-β1/BMP-7: F(2,20)=8.9, p<0.01; TGF-β2/BMP-7: 
F(2,21)=14.6, p<0.001.  
C: ANOVA followed by Bonferroni’s test. 
p-Smad 1/5/8: F(2,12)=15.5, p<0.001; p-Smad 2/3: F(2,12)=7.6, p<0.05; and 
Smad 7: mRNA: F(2,18)=7.3, p<0.01. 
 
Figure 3: ANOVA followed by Bonferroni’s test. 
ANP: F(2,14)=11.4, p<0.01; BNP: F(2,14)=9.7, p<0.01; β-MHC: F(2,14)=4.4, 
p<0.05. Luciferase Activity: F(2,13)=3.8, p<0.05. 
 
Figure 4 
A: Two way repeated-measures ANOVA followed by Bonferroni’s test.  
LV mass: TAC-saline vs. TAC-BMP-71-4wk: (Interaction: F(4,44)=22.9, p<0.001; 
Follow-up time: F(4,44)=133.7 p<0.001; Treatment: F(1,44)=27.3, p<0.001); 
TAC-saline vs. TAC-BMP-73-4wk: (Interaction: F(2,28)=6.8, p<0.001; Follow-up 
time: F(2,28)=4.2, p<0.001; Treatment: F(1,14)=30.0, p<0.05).  
Posterior wall thicknesses: TAC-saline vs. TAC-BMP-71-4wk: (Interaction: 
F(4,44)=9.8, p<0.001; Follow-up time: F(4,44)=143.7 p<0.001; Treatment: 
F(1,44)=36.8, p<0.001); TAC-saline vs. TAC-BMP-73-4wk: (Interaction: 
F(2,28)=3.4, p<0.05). 
LV end systolic diameter: TAC-saline vs. TAC-BMP-71-4wk: (Interaction: 
F(4,44)=15.0, p<0.001; Follow-up time: F(4,44)=16.9 p<0.001; Treatment: 
F(1,44)=27.9, p<0.001); TAC-saline vs. TAC-BMP-73-4wk: (Interaction: 
F(2,28)=3.7, p<0.01; Follow-up time: F(2,28)=4.7, p<0.01; Treatment: 
F(1,14)=30.7, p<0.05). 
LV end diastolic diameter: TAC-saline vs. TAC-BMP-71-4wk (Interaction: 
F(4,44)=16.3, p<0.001; Follow-up time: F(4,44)=15.3 p<0.001; Treatment: 
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F(1,44)=24.2, p<0.001); TAC-saline vs. TAC-BMP-73-4wk: (Follow-up time: 
F(2,28)=9.5, p<0.001). 
LV ejection fraction: TAC-saline vs. TAC-BMP-71-4wk: (Interaction: F(4,44)=8.1, 
p<0.001; Follow-up time: F(4,44)=11.7, p<0.001; Treatment: F(1,44)=21.9, 
p<0.001); TAC-saline vs. TAC-BMP-73-4wk: (Interaction: F(2,28)=9.5, p<0.001; 
Treatment: F(1,14)=27.1, p<0.05). 
Mitral annular plane systolic excursion: TAC-saline vs. TAC-BMP-71-4wk: 
(Interaction: F(4,44)=9.4, p<0.001; Follow-up time: F(4,44)=40.0, p<0.001; 
Treatment: F(1,44)=13.4, p<0.01), TAC-saline vs. TAC-BMP-73-4wk: (Treatment 
F(1,14)=19.6, p<0.05). 
Ratio of peak early transmitral flow velocity (E) to peak early myocardial tissue 
velocity (e′): TAC-saline vs. TAC-BMP-71-4wk: (Interaction: F(4,44)=12.1, 
p<0.001; Follow-up time: F(4,44)=20.2, p<0.001; Treatment: F(1,44)=50.5, 
p<0.001); TAC-saline vs. TAC-BMP-73-4wk: (Interaction: F(4,56)=2.6, p<0.05; 
Follow-up time: F(4,56)=66.5, p<0.001; Treatment: F(1,44)=50.5, p<0.001). 
Mean trans-coarctation pressure gradient: TAC-saline vs. TAC-BMP-71-4wk: 
(Follow-up time: F(4,44)=190.2, p<0.001), TAC-saline vs. CAT-BMP-73-4wk: 
(Follow-up time: F(2,30)=10.5, p<0.001).  
B: Two way repeated-measures ANOVA followed by Bonferroni’s test. Pressure 
gradient: (Follow-up time: F(4,112)=205,4 p<0,001).  
LV posterior wall thickness: (Follow-up time: F(4,112)=90.7, p<0.001; 
Genotype: F(1,112)=13.9, p<0.001).  
IVS: Follow-up time: F(4,112)=195,1 p<0,001; Genotype: F(1,28)=21,8 p<0,001. 
Relative PWT to LVED radius: (Follow-up time: F(4,112)=30.1, p<0.001; 
Genotype: F(1,112)=8.9, p<0.01).  
LV ejection fraction (Follow-up time: F(4,112)=72.2, p<0.001).  
Mitral annular plane systolic excursion (Follow-up time: F(4,112)=111.7, 
p<0.001).  
Ratio of peak early transmitral flow velocity (E) to peak early myocardial tissue 
velocity (e′) (Follow-up time: F(4,112)=81.9, p<0.001).  
 
Figure 5: ANOVA followed by Bonferroni’s test. 
TGF-β1: F(3,33)=5.2, p<0.01; TGF-β2: F(3,24)=7.9, p<0.001; Col I: 
F(3,29)=6.7, p<0.01; Col III: F(3,24)=12.8, p<0.001; FN1: F(3,21)=8.0, p<0.01; 
β-MHC: F(3,24)=16.0, p<0.001; histological fibrosis: F(3,24)=6.1, p<0.01; 
cardiomyocyte diameter: F(3,16)=19.8, p<0.001]  
 
Figure 6 
A: One way ANOVA followed by Bonferroni’s test. 
LV hypertrophy regression after de-TAC: F(3,25)=15.03, p<0.001.  
Recovery of systolic function in the short axis (LVEF): F(3,24)=10.2, p<0.001. 
Recovery of systolic function in the long axis (MAPSE): F(3,24)=5.5, p<0.01. 
Reduction of LV loading pressure (E/e’): F(3,25)=3.0, p<0.05.  
B: One way ANOVA followed by Bonferroni’s test. 
Histological fibrosis: F(7,40)=13.9, p<0.001; cardiomyocyte diameter: 
F(7,42)=14.8, p<0.01).  
